Solvonis Therapeutics plc (GB:SVNS)
LSE:SVNS
Want to see GB:SVNS full AI Analyst Report?
SVNS Stock Chart & Stats
0.35 p
--
Market closed
0.35 p
--
Day’s Range― - ―
52-Week Range0.17 p - 0.40 p
Previous CloseN/A
VolumeN/A
Average Volume (3M)34.43M
Market Cap
£12.86M
Enterprise Value12.65M
Total Cash (Recent Filing)£757.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,806,403,300
10 Day Avg. Volume23,401,787
30 Day Avg. Volume34,434,652
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt reduces financial risk and preserves balance-sheet flexibility over the medium term. This provides the company more runway to execute restructuring, R&D or pursue partnerships without immediate refinancing pressure, supporting strategic options despite operating losses.
Growing Equity BufferA meaningful increase in equity improves solvency and provides a capital buffer against continued losses. Over a 2–6 month horizon this equity cushion supports operational continuity, potential investment in product development, and resilience to cash-flow variability.
Very Lean HeadcountA tiny employee base implies a low fixed-cost structure and operational flexibility. This lean setup can extend cash runway and allow management to reallocate or scale costs quickly, which is durable advantage when addressing structural revenue weakness or pivoting business strategy.
Bears Say
Persistent Losses And Collapsed RevenueSustained operating and net losses combined with revenue that has fallen to effectively zero indicate a fundamental breakdown in demand or commercialization. Without a credible path to restore revenue, the core business model's ability to generate profits is impaired over the medium term.
Consistent Negative Cash GenerationOngoing negative operating cash flow and worsening free cash flow increase reliance on external financing or equity raises. Over months this limits strategic flexibility, risks dilution if capital is raised, and can force cutbacks that impair long-term recovery or investment plans.
Negative Returns On EquityDespite a growing equity base, strongly negative ROE shows capital is not producing returns. If losses persist this will erode the equity buffer, reduce investor confidence, and constrain long-term funding options and the firm's ability to sustain operations or invest in growth.
Solvonis Therapeutics News
SVNS FAQ
What was Solvonis Therapeutics plc’s price range in the past 12 months?
Solvonis Therapeutics plc lowest share price was 0.17 p and its highest was 0.40 p in the past 12 months.
What is Solvonis Therapeutics plc’s market cap?
Solvonis Therapeutics plc’s market cap is £12.86M.
When is Solvonis Therapeutics plc’s upcoming earnings report date?
Solvonis Therapeutics plc’s upcoming earnings report date is Sep 24, 2026 which is in 93 days.
How were Solvonis Therapeutics plc’s earnings last quarter?
Solvonis Therapeutics plc released its earnings results on Apr 29, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Solvonis Therapeutics plc overvalued?
According to Wall Street analysts Solvonis Therapeutics plc’s price is currently Overvalued.
Does Solvonis Therapeutics plc pay dividends?
Solvonis Therapeutics plc does not currently pay dividends.
What is Solvonis Therapeutics plc’s EPS estimate?
Solvonis Therapeutics plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics plc have?
Solvonis Therapeutics plc has 6,806,403,300 shares outstanding.
What happened to Solvonis Therapeutics plc’s price movement after its last earnings report?
Solvonis Therapeutics plc reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.781%.
Which hedge fund is a major shareholder of Solvonis Therapeutics plc?
Currently, no hedge funds are holding shares in GB:SVNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics plc
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Technical Analysis
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―
Options Prices
Currently, No data available
---